BHVN Straddle Strategy
BHVN (Biohaven Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
BHVN (Biohaven Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.96B, a beta of 3.17 versus the broader market, a 52-week range of 7.48-18.57, average daily share volume of 3.1M, a public-listing history dating back to 2022, approximately 274 full-time employees. These structural characteristics shape how BHVN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 3.17 indicates BHVN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on BHVN?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
BHVN snapshot
As of September 29, 2026, spot at $13.25, ATM IV 81.40%, IV rank 4.50%, expected move 23.34%. The straddle on BHVN below is built from the September 29, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this straddle structure on BHVN specifically: BHVN IV at 81.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a BHVN straddle, with a market-implied 1-standard-deviation move of approximately 23.34% (roughly $3.09 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BHVN expiries trade a higher absolute premium for lower per-day decay. Position sizing on BHVN should anchor to the underlying notional of $13.25 per share and to the trader's directional view on BHVN stock.
BHVN straddle setup
The BHVN straddle below is built from the September 29, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BHVN at $13.25 on that close, the first option leg uses a $13.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BHVN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BHVN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $13.00 | $1.10 |
| Buy 1 | Put | $13.00 | $0.73 |
BHVN straddle risk and reward
- Net Premium / Debit
- -$182.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$176.97
- Breakeven(s)
- $11.18, $14.83
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
BHVN straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on BHVN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | +$1,116.50 |
| $2.94 | -77.8% | +$823.65 |
| $5.87 | -55.7% | +$530.79 |
| $8.80 | -33.6% | +$237.94 |
| $11.72 | -11.5% | -$54.92 |
| $14.65 | +10.6% | -$17.23 |
| $17.58 | +32.7% | +$275.63 |
| $20.51 | +54.8% | +$568.48 |
| $23.44 | +76.9% | +$861.33 |
| $26.37 | +99.0% | +$1,154.19 |
When traders use straddle on BHVN
Straddles on BHVN are pure-volatility plays that profit from large moves in either direction; traders typically buy BHVN straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
BHVN thesis for this straddle
The market-implied 1-standard-deviation range for BHVN extends from approximately $10.16 on the downside to $16.34 on the upside. A BHVN long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current BHVN IV rank near 4.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BHVN at 81.40%. As a Healthcare name, BHVN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BHVN-specific events.
BHVN straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BHVN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BHVN alongside the broader basket even when BHVN-specific fundamentals are unchanged. Always rebuild the position from current BHVN chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on BHVN?
- A straddle on BHVN is the straddle strategy applied to BHVN (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With BHVN stock at $13.25 on the September 29, 2026 close, the strikes shown on this page are snapped to the nearest listed BHVN chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are BHVN straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the BHVN straddle priced from the September 29, 2026 end-of-day chain at a 30-day expiry (ATM IV 81.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$176.97 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BHVN straddle?
- The breakeven for the BHVN straddle priced on this page is roughly $11.18 and $14.83 at expiration, derived from the September 29, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BHVN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 23.34%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on BHVN?
- Straddles on BHVN are pure-volatility plays that profit from large moves in either direction; traders typically buy BHVN straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current BHVN implied volatility affect this straddle?
- BHVN ATM IV is at 81.40% with IV rank near 4.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.